Trial Profile
A Phase I Study of 131I-MIBG With Dinutuximab +/- Vorinostat for Relapsed/Refractory Neuroblastoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 22 Aug 2023
Price :
$35
*
At a glance
- Drugs Dinutuximab (Primary) ; Iobenguane (Primary) ; Sargramostim (Primary) ; Vorinostat (Primary)
- Indications Neuroblastoma
- Focus Adverse reactions
- 10 Mar 2023 Status changed from recruiting to active, no longer recruiting.
- 30 Jan 2023 Planned End Date changed from 1 Mar 2023 to 1 Jun 2024.
- 30 Jan 2023 Planned primary completion date changed from 1 Sep 2022 to 1 Jun 2023.